Results 161 to 170 of about 55,815 (216)

Enocyanin Synergistically Enhances Sorafenib Sensitivity in Hepatocellular Carcinoma via Ferroptosis Induction Associated with p62/Keap1/Nrf2/HO-1 Pathway Inhibition. [PDF]

Curr Issues Mol Biol
Tian M, Ma J, Wei T, Meng K, Xia Y, Zong X, Bai C, Wang Z.   +7 more
europepmc   +1 more source

Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs. [PDF]

BMC Gastroenterol
Zhong Q, Li H, Hu W, Li Z, Hu Z.
europepmc   +1 more source

Cost-effectiveness analysis of toripalimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. [PDF]

Front Public Health
Wu C, Wei T, Ye X, Dong Z, Chen X.
europepmc   +1 more source

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. [PDF]

PLoS One
Xu X, Tang L, Piao X, Zhan S, Chen Y, Feng P.   +5 more
europepmc   +1 more source

Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves. [PDF]

Front Med (Lausanne)
Zhou W, Xu P.
europepmc   +1 more source

USP25 aggravates liver cancer development and impairs chemosensitivity by limiting LATS1 activation. [PDF]

EMBO Rep
Li L, Wang X, Yang Y, Zhou Y, Jiang Z, Zhai L, Zhao X, Qiang H, Luo J, Ji Y, Yao J, Zhang T, Wang Y, Li K, Chen L, Chen Y, Yuan J, Li Y.   +17 more
europepmc   +1 more source

Angiogenic Prognostic Signature for Stratification in Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Zhu Z, Guo C, Shen H, Zeng S, Li N.
europepmc   +1 more source

Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma. [PDF]

Cancer Immunol Immunother
Fan TC, Hung TH, Yeh CT, Lin PT, Chang NC, Lo TC, Wu TJ, Yu J, Yu AL.   +8 more
europepmc   +1 more source

<i>In silico</i> study of <i>Spatholobus littoralis</i> Hassk. wood compounds on p38 mitogen-activated protein kinase receptor. [PDF]

J Adv Pharm Technol Res
Ervina M, Firdaus MA, Caroline, Siswandono, Wiranata BI.   +4 more
europepmc   +1 more source

Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study. [PDF]

Front Med (Lausanne)
Chen J, Xu Q, Wang B, Sun H, Shu Q.
europepmc   +1 more source